Background: Immunocompromising conditions and advanced age (>= 65 years) are associated with a high risk for invasive pneumococcal disease (IPD). We investigated the risk and outcomes of IPD in adults with underlying conditions in the post-PCV7 era in The Netherlands.Methods: IPD data from 2008 to 2012 was obtained from the national pneumococcal surveillance system, covering 25% of the Dutch population. Population estimates of underlying conditions were derived from the primary care data (2012). IPD incidence in adults with immunocompromising conditions (high risk group) and non-immunocompromising comorbidities (medium risk group) were compared to the "normal risk group" without diagnosed comorbidities. Case-fatality and ICU admission in...
The elderly and adults with medical risk conditions remain at high risk of invasive pneumococcal dis...
Serotypes/genotypes causing invasive pneumococcal disease (IPD) in adults are determined by vaccina-...
BACKGROUND In Switzerland, the heptavalent (PCV7) and 13-valent pneumococcal conjugate vaccine (P...
Background: Immunocompromising conditions and advanced age (>= 65 years) are associated with a hi...
Background Implementation of 7-valent pneumococcal conjugate vaccine (PCV7) in the Dutch national im...
With a retrospective study of invasive pneumococcal disease (IPD) surveillance data representative f...
AbstractBackgroundIn Switzerland, the heptavalent (PCV7) and 13-valent pneumococcal conjugate vaccin...
Background: Recently, the 13-valent pneumococcal conjugate vaccine (PCV13) has been recommended for ...
BACKGROUND: England is experiencing a rapid increase in invasive pneumococcal disease (IPD) caused b...
Background: Adult invasive pneumococcal disease (IPD) occurs mainly in the elderly and patients with...
Background. The Streptococcus pneumoniae polysaccharide capsule may be related to invasive pneumococ...
We studied the possible association between patient age and sex, clinical presentation, Streptococcu...
The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in The Netherlands in 2006 and was...
In the Netherlands, the national immunization program includes 7-valent pneumococcal conjugate vacci...
Streptococcus pneumoniae is the most frequently detected human pathogen in respiratory infections wi...
The elderly and adults with medical risk conditions remain at high risk of invasive pneumococcal dis...
Serotypes/genotypes causing invasive pneumococcal disease (IPD) in adults are determined by vaccina-...
BACKGROUND In Switzerland, the heptavalent (PCV7) and 13-valent pneumococcal conjugate vaccine (P...
Background: Immunocompromising conditions and advanced age (>= 65 years) are associated with a hi...
Background Implementation of 7-valent pneumococcal conjugate vaccine (PCV7) in the Dutch national im...
With a retrospective study of invasive pneumococcal disease (IPD) surveillance data representative f...
AbstractBackgroundIn Switzerland, the heptavalent (PCV7) and 13-valent pneumococcal conjugate vaccin...
Background: Recently, the 13-valent pneumococcal conjugate vaccine (PCV13) has been recommended for ...
BACKGROUND: England is experiencing a rapid increase in invasive pneumococcal disease (IPD) caused b...
Background: Adult invasive pneumococcal disease (IPD) occurs mainly in the elderly and patients with...
Background. The Streptococcus pneumoniae polysaccharide capsule may be related to invasive pneumococ...
We studied the possible association between patient age and sex, clinical presentation, Streptococcu...
The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in The Netherlands in 2006 and was...
In the Netherlands, the national immunization program includes 7-valent pneumococcal conjugate vacci...
Streptococcus pneumoniae is the most frequently detected human pathogen in respiratory infections wi...
The elderly and adults with medical risk conditions remain at high risk of invasive pneumococcal dis...
Serotypes/genotypes causing invasive pneumococcal disease (IPD) in adults are determined by vaccina-...
BACKGROUND In Switzerland, the heptavalent (PCV7) and 13-valent pneumococcal conjugate vaccine (P...